Drug Target Review

JUNE 11, 2025

Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Highlighting data integration.

Drugs 64

Drugs Clinical Trials Drug Development Pharmaceuticals 64

Alta Sciences

JUNE 26, 2025

AI was the focus of more than 70 poster and paper presentations, highlighting its growing impact in the field. These presentations demonstrated how advanced machine learning models are being deployed to enhance diagnostic accuracy, especially in early glaucoma detection. conference locations.

Drug Development 52

Drug Development Drugs Science Therapies 52

Drug Patent Watch

DECEMBER 9, 2024

This approach has led to the discovery of numerous potential drug candidates. From Lab to Market: The Long Road of Drug Development Once a promising compound is identified, it enters the long and costly process of drug development. Q: How long does a drug patent last?

Drugs 94

Drugs Drug Development Pharmaceuticals Production 94

Drug Target Review

JUNE 17, 2025

For example, a tumour’s resistance to therapy may not stem from its mutational profile alone but from its interaction with surrounding stroma or immune cells – invisible interactions in dissociated, bulk sequencing data. Integrated multiomics is the future The impact on drug development could be profound.

RNA 71

RNA Engineering DNA Disease 71

Drug Target Review

DECEMBER 23, 2024

Antibody-drugconjugates (ADCs) represent a significant advancement in drug discovery, combining the precision of monoclonal antibodies with the cancer-killing power of cytotoxic drugs. Wangs research focuses on developing mechanistic mathematical models to quantitatively characterise ADC-induced toxicities.

Research 52

Research Treatment Therapies Drug Development 52

SugarCone Biotech

JUNE 19, 2025

They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attacking these targets have been developed. SCLC generally has a “hot” tumor microenvironment (TME) meaning that it is infiltrated by immune cells, including the T cells that are activated by immune checkpoint therapies.

Therapies 78

Therapies Clinical Trials Treatment Clinical Development 78

The Pharma Data

JUNE 26, 2025

With more than 40 clinical and commercial-stage assets in active development, BeOne Medicines is demonstrating a scale of ambition matched by few in the field. BeOne Medicines’ rise has been fueled by a strategic commitment to innovation at every level of the drug development continuum.

Research 40

Research Clinical Development Clinical Trials Engineering 40

Alta Sciences

JULY 3, 2025

Altasciences At CPHI Americas 2025 pmjackson Thu, 07/03/2025 - 13:41 In the ever-changing drug development world, staying agile is essential to enabling more informed decisions, faster. It’s a challenge that affects a large percentage of new drug candidates—one we’re passionate about helping to solve. The response?

Small Molecule 52

Small Molecule Drug Development Pharmaceuticals Science 52

Conversations in Drug Development Trends

NOVEMBER 12, 2024

By Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Rare Disease Cell and gene therapies (CGTs) include cutting-edge approaches that offer the hope of a healthier, happier, and better tomorrow for a wide range of patient populations. Below, we discuss some of these challenges in cell therapy trials.

Therapies 72

Therapies Clinical Supply Clinical Trials Trials 72

Drug Target Review

JUNE 28, 2025

DARPin therapeutics were a prominent theme at AACR 2025 , with Molecular Partners presenting a trio of preclinical programmes spanning radiopharmaceuticals and immune cell engagers. “My passion for science drew me to DARPin technology, and I was eager to contribute to the development of new DARPin therapies.”

Science 52

Science Engineering Treatment Clinical Development 52

Drug Target Review

DECEMBER 16, 2024

Dr Pooja Hingorani, Senior Medical Director of Oncology Early Development at AbbVie , shares her journey in STEM, from her early days in New Delhi to her impactful career in oncology research and drug development. Opportunities in clinical research and drug development were not always easy to come by.

Medical Schools 52

Medical Schools Clinical Research Drug Development Trials 52

The Pharma Data

JUNE 27, 2025

These data offer new hope to the CDD community, which has long struggled with a lack of effective seizure control therapies. The lack of approved therapies specifically indicated for CDD means that treatment strategies are often based on off-label use of anti-seizure medications, with limited success.

Trials 40

Trials Treatment Therapies Pharmacokinetics 40

Drug Target Review

APRIL 14, 2025

This model not only promises a broader market but also presents tangible benefits for patients. By preventing infections before they occur, these drugs reduce the need for hospital treatments, including the costly intensive care unit (ICU) care that can burden healthcare systems.

Therapies 52

Therapies Marketing Drug Development Treatment 52

Drug Target Review

JUNE 5, 2025

Despite recent advances in gene therapy for sickle cell disease (SCD) , automated red blood cell exchange (aRBCX) remains a cornerstone therapy that plays a vital yet underutilised role in managing complications and enhancing quality of life for millions living with this devastating condition worldwide.

Disease 52

Disease Treatment Therapies Nurses 52

Conversations in Drug Development Trends

OCTOBER 29, 2024

Increasingly, patients and patient-led organizations are playing a pivotal role in shaping drug development, underscoring the importance of collaboration between patient organizations, CROs, and pharmaceutical and biotechnology companies.

Clinical Research 72

Clinical Research Disease Research Clinical Trials 72

The Premier Consulting Blog

JANUARY 14, 2025

Established in 2017 under the 21st Century Cures Act, the OCE brings together multidisciplinary scientific expertise to accelerate the review and approval of drugs, biologics, and medical devices for cancer care. These reviews have provided life-saving cancer therapies a median of 3.1 Program What is it?

Clinical Trials 52

Clinical Trials Therapies FDA Trials 52

Alta Sciences

DECEMBER 31, 2024

In Issue 7 of The Altascientist , we delve into these factors, the importance of drug interaction studies, and how to limit adverse effects and maximize treatment response. The potential for an investigational drug to cause DDIs should be investigated in a stepwise manner during drug development.

Therapies 52

Therapies Pharmacokinetics Pharmacogenetics Clinical Trials 52

BioPharma Drive: Drug Pricing

JULY 14, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. and elsewhere in its 2025 fiscal year and plans to present detailed results at an upcoming medical meeting.

Drugs 187

Drugs Clinical Trials Therapies Licensing 187

DrugBank

JUNE 18, 2025

Drug development is a complex and highly regulated process. Before a therapy can be approved for patient use, it must undergo extensive clinical testing and strictly adhere to regulatory guidelines. One of the most significant challenges in drug development is global regulatory variability.

Drug Development 52

Drug Development Clinical Trials Compliance Drugs 52

Codon

NOVEMBER 3, 2024

As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drug developers. These challenges have led to strategies such as directly observed therapy (DOT), in which nurses or physicians monitor patients to ensure they take their medicine every day.

Vaccine 114

Vaccine Trials Therapies Treatment 114

Drug Patent Watch

DECEMBER 17, 2024

Contract Development and Manufacturing Organizations (CDMOs) are at the forefront of this shift, playing a crucial role in bringing innovative therapies to market. Today, they’re strategic partners in drug development and manufacturing, offering end-to-end solutions that can make or break a pharmaceutical company’s success.

Pharmaceuticals 75

Pharmaceuticals Therapies Production Pharmaceutical Companies 75

Drug Target Review

MAY 26, 2025

With a particular focus on biologics, cell, and gene therapies, Galbraiths work is centred on equipping drug developers with the tools, insights, and support needed to advance their therapies from concept to clinic. We are driving rapid analytics to support the release of cell and gene therapies and other biologics.

Drug Development 52

Drug Development Drugs Therapies Pharmaceuticals 52

Alta Sciences

APRIL 24, 2025

Case Study: How Altasciences Overcame Pharmacological Challenges in a GLP-1 IND-Enabling Study pmjackson Thu, 04/24/2025 - 21:43 For emerging therapies with pronounced pharmacological effects, thoughtful study design is critical to ensuring reliable and interpretable data.

Small Molecule 52

Small Molecule Pharmacokinetics Treatment Compliance 52

BioPharma Drive: Drug Pricing

JUNE 26, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. Progress developing a treatment for leukemia led the company in 2021 to price a $177 million initial public offering.

Disease 109

Disease Licensing Licensing Therapies 109

BioPharma Drive: Drug Pricing

JULY 9, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. billion purchase of Intra-Cellular Therapies , according to data tracked by BioPharma Dive.

Clinical Trials 277

Clinical Trials Drugs Therapies Licensing 277

BioPharma Drive: Drug Pricing

JUNE 26, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. says US won’t donate to global vaccine effort View all Events 07 JUL Webinar | 10 a.m.

Licensing 117

Licensing Licensing Therapies Vaccine 117

BioPharma Drive: Drug Pricing

JUNE 27, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. On June 26, 2025, the Food and Drug Administration eased some of the medicines' reporting requirements.

Therapies 178

Therapies FDA Treatment Licensing 178

Conversations in Drug Development Trends

APRIL 8, 2025

In a recent webinar, Challenges of Drug Development in Early Parkinsons Disease , Tom Babic, MD, PhD , our Vice President of Scientific Solutions in Neuroscience, uses his 40+ years of experience to share invaluable insights into the current state and future directions of early Parkinsons disease (PD) research.

Research 49

Research Clinical Trials Trials Treatment 49

Conversations in Drug Development Trends

APRIL 7, 2025

Solid tumors present a significant challenge to clinical research due to their complex and heterogeneous nature. This approach improves treatment outcomes over traditional broad-spectrum therapies, which are prone to more side effects and adverse events.

Research 40

Research Clinical Trials Trials Clinical Research 40

Perficient: Drug Development

APRIL 15, 2025

Defining Long COVID: Clinical Criteria and Diagnostic Challenges Long COVID, as defined by the US Department of Health and Human Services, encompasses signs, symptoms, and conditions present for a minimum of four weeks after initial SARS-CoV-2 infection.

Immune Response 52

Immune Response Treatment Therapies Research 52

Codon

JULY 14, 2025

When researchers gave people willow bark extract corresponding to 240 mg of salicin, then looked at how much salicylic acid was present in their blood over time, it was the equivalent of taking 87 mg of aspirin ( 300 mg to 600 mg is recommended per dose, with up to 3600 mg allowed per day).

Treatment 83

Treatment Laboratories Disease Drugs 83

Conversations in Drug Development Trends

APRIL 28, 2025

From the presentation of the REVERSE-IT and STRIDE trials to additional studies on lipid-lowering therapies and heart failure treatments, this webinar reflected on key study results and their implications for future cardiovascular research.

Trials 40

Trials Therapies Clinical Trials Treatment 40

BioPharma Drive: Drug Pricing

SEPTEMBER 16, 2024

Applying CAR T-cell therapy in new clinical settings presents unique challenges. Worldwide Clinical Trials is at the forefront, partnering with drug development teams to map this new path forward.

Therapies 130

Therapies Trials Clinical Trials Drug Development 130

PPD

OCTOBER 17, 2024

Cell and gene therapy (CGT) studies are rapidly gaining momentum in the Asia-Pacific region, fueled by growing patient demand and a thriving ecosystem of innovation. In China, the high incidence of solid tumors is driving an urgent need for advanced therapies, spurring the push for new treatment approaches.

Therapies 97

Therapies Clinical Trials Clinical Research Trials 97

PPD

SEPTEMBER 25, 2023

As the clinical trial landscape evolves, drug developers are faced with novel challenges and changes in study recruitment, trial size and structure, and more. The adoption of new innovations, strategies and technologies offers opportunities to address persistent challenges and develop suitable approaches for the future.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. Part of the challenge is that patients present with very different kinds of clinical phenotypes, meaning the populations are heterogeneous.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Therapies 119

Therapies FDA FDA Approval Treatment 119